Detalhe da pesquisa
1.
Fexapotide triflutate vs oral pharmacotherapy as initial therapy for moderate-to-severe benign prostate hyperplasia patients: a cost-effectiveness analysis.
BMC Urol
; 22(1): 76, 2022 May 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35550071